Basu, Bristi

Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study

Walter, F. M., Mills, K., Mendonça, S. C., Abel, G. A., Basu, B., Carroll, N., Ballard, S., Lancaster, J., Hamilton, W., Rubin, G. P., et al. (2016) · The Lancet Gastroenterology & Hepatology

Pancreatic and Hepatic Oncology ResearchGlobal Cancer Incidence and Screening

Cited by 174

Intermittent schedules of the oral RAF–MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study

Guo, C., Chénard-Poirier, M., Roda, D., de Miguel, M., Harris, S. J., Candilejo, I. M., Sriskandarajah, P., Xu, W., Scaranti, M., Constantinidou, A., et al. (2020) · The Lancet Oncology

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 78

PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC)

Basu, B., Gourley, C., Gabra, H., Vergote, I. B., Brenton, J. D., Abrahmsen, L., Smith, A., Von Euler, M., & Green, J. A. (2016) · Annals of Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 8